17 September 2019
There is finally some encouraging news for the millions of Americans suffering from Alzheimer’s Disease. NeuroEM Therapeutics today announced findings from an open label clinical trial showing reversal of cognitive impairment in Alzheimer’s disease patients after just two months of treatment using the company’s wearable head device for in-home treatment.
3 September 2019
Globally, dementia cases are increasing at a rate of more than 20% a year. Most of these cases are in low- to middle-income countries. In a special supplement to the Journal of Alzheimer’s Disease, from the International Research Network on Dementia Prevention (IRNDP), an international group of scientists presents new research from around the world examining the potential risk factors for dementia and how to reduce them.
23 August 2019
For older Americans, poor handgrip may be a sign of impaired cognition and memory, a new study suggests. Researchers from the University of Michigan and North Dakota State University followed nearly 14,000 participants from the 2006 Health and Retirement Study, age 50 and older, for eight years. They found that every 5-kg reduction in handgrip strength was associated with 10% greater odds for any cognitive impairment and 18% greater odds for severe cognitive impairment.
14 August 2019
Migraine Diagnoses Positively Associated with All-Cause Dementia and Alzheimer’s Disease in Women in the UK
Several studies have recently focused on the association between migraine headaches and other headaches and dementia and found a positive migraine-dementia relationship. However, most of these studies have failed to simultaneously adjust for several common comorbidities, thus potentially introducing bias into their findings.
6 August 2019
Measuring the Brain’s Amyloid Buildup Less Effective in Identifying Severity, Progression of Alzheimer’s Disease Compared to Other Imaging Methods
Researchers find fluorodeoxyglucose (FDG) PET is a better indicator of cognitive performance for patients with Alzheimer’s disease, mild cognitive impairment, when compared to PET scans that detect amyloid protein.
30 July 2019
To keep our JAD editors, authors, and readers informed of JAD's progress and development, the journal hereby shares the 2019 editorial update.
30 July 2019
Controlling body weight in older age may help to prevent new dementia, a new study suggests. The research, led by the University of Wolverhampton, examined 38,219 participants and 4,479 dementia cases worldwide, through a systematic search and review.
29 July 2019
A new research review highlighting the hidden costs of dementia suggests that traditional measures only show the “tip of the iceberg” of the cost impact on society. The analysis, from an international team of experts from academia, research institutes, health care organizations, consulting firms and Alzheimer’s Research UK, looked at the true cost of Alzheimer’s disease and Related Dementias (ADRD).
15 July 2019
Journal of Alzheimer’s Disease Partners with Advanced Continuing Education Association to Launch New CME Article Series
The Journal of Alzheimer’s Disease (JAD) is pleased to announce a new partnership with Advanced Continuing Education Association (ACEA) to provide a new series of fully accredited continuing medical education (CME) journal articles. The program, accredited under the ACCME and open to US and Canadian physicians, launches today with 10 landmark articles published in JAD, each with a corresponding CME post-test providing 1.0 AMA PRA Category 1 Credit™.
2 July 2019
The Journal of Alzheimer’s Disease (JAD) is pleased to announce that Yan-Jiang Wang, MD, PhD, and Xian-Le Bu, MD, PhD, both of Daping Hospital, Third Military Medical University, Chongqing, China, are joint recipients of the 2019 Alzheimer Award. The award is presented by the journal in recognition of Dr. Wang, Dr. Bu, and colleagues’ groundbreaking article that presents clear evidence that gut microbiota composition is altered in patients with Alzheimer’s disease (AD). This suggests that gut microbiota participate in the disease pathogenesis, and modulation of gut microbiota might be a potential therapeutic strategy for AD.